IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Chevy Chase Trust Holdings LLC

Chevy Chase Trust Holdings LLC lessened its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 6.3% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 98,278 shares of the medical research company's stock after selling 6,649 shares during the quarter. Chevy Chase Trust Holdings LLC owned approximately 0.05% of IQVIA worth $23,289,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in IQV. Versant Capital Management Inc raised its position in shares of IQVIA by 733.3% in the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company's stock worth $26,000 after buying an additional 110 shares during the period. Opal Wealth Advisors LLC purchased a new position in shares of IQVIA in the 2nd quarter worth $27,000. Capital Performance Advisors LLP purchased a new position in shares of IQVIA in the 3rd quarter worth $27,000. Park Place Capital Corp purchased a new position in shares of IQVIA in the 3rd quarter worth $28,000. Finally, Itau Unibanco Holding S.A. purchased a new position in shares of IQVIA in the 2nd quarter worth $29,000. Hedge funds and other institutional investors own 89.62% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on IQV shares. Evercore ISI cut their target price on IQVIA from $270.00 to $265.00 and set an "outperform" rating on the stock in a research report on Tuesday, October 8th. Barclays cut their price objective on IQVIA from $260.00 to $255.00 and set an "overweight" rating on the stock in a research report on Friday, November 1st. TD Cowen cut their price objective on IQVIA from $270.00 to $255.00 and set a "buy" rating on the stock in a research report on Friday, November 1st. Leerink Partners reissued an "outperform" rating and issued a $248.00 price objective (down from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Finally, Morgan Stanley cut their price objective on IQVIA from $280.00 to $265.00 and set an "overweight" rating on the stock in a research report on Monday, November 4th. Five equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, IQVIA currently has a consensus rating of "Moderate Buy" and a consensus price target of $256.50.

IQVIA Stock Performance

Shares of NYSE IQV traded up $2.59 during midday trading on Wednesday, hitting $203.17. 1,039,121 shares of the company's stock were exchanged, compared to its average volume of 1,178,884. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The stock's 50 day moving average price is $216.54 and its 200-day moving average price is $225.51. The firm has a market cap of $36.88 billion, a P/E ratio of 26.66, a PEG ratio of 2.08 and a beta of 1.49. IQVIA Holdings Inc. has a twelve month low of $187.62 and a twelve month high of $261.73.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.